Publication demonstrates robust and reproducible generation of pure pallial, medial ganglionic eminence (MGE)-type GABAergic inhibitory interneuron cell therapy candidate derived from a clinical-grade human stem cell line Preclinical data demonstrate significant suppression of focal seizures, decreased neuropathology, and increased survival following cell transplantation into a chronic model of mesial temporal lobe epilepsy (MTLE) Study supports an ongoing open-label first-in-human Phase I/II trial of NRTX-1001 in adults with drug-resistant MTLE, which has shown promising early clinical data SAN FRANCISCO, Oct.

该出版物证明了源自临床级人类干细胞系的纯苍白，内侧神经节隆起（MGE）型GABA能抑制性中间神经元细胞治疗候选物的强大且可重现的产生。临床前数据表明，局灶性癫痫发作显着抑制，神经病理学降低，并且在细胞移植到内侧颞叶癫痫（MTLE）慢性模型中后存活率增加研究支持NRTX-1001在具有耐药性MTLE的成人中进行的正在进行的开放标签的首次人体I/II期试验，其显示出有希望的早期临床数据旧金山，Oct。

05, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the publication of the development and characterization of a highly purified population of human stem cell-derived, pallial-specific MGE inhibitory interneurons for the potential treatment of focal epilepsy.

052023（GLOBE NEWSWIRE）-Neurona Therapeutics是一家临床阶段生物治疗公司，致力于推进用于治疗神经系统疾病的再生细胞治疗候选药物，今天宣布开发和表征高度纯化的人类干细胞衍生，pallial特异性MGE抑制性中间神经元用于局灶性癫痫的潜在治疗。

In a preclinical study, administration of a single dose of the cells in a chronic model of drug-resistant MTLE resulted in durable and consistent suppression of focal seizures, as well as improvements in neuropathology and an increase in survival of the model. The study also demonstrated a potentially broad, safe and effective dosing range in the preclinical model.

在临床前研究中，在耐药性MTLE的慢性模型中施用单剂量的细胞导致局灶性癫痫发作的持久且一致的抑制，以及神经病理学的改善和模型存活的增加。该研究还证明了临床前模型中潜在的广泛，安全和有效的剂量范围。

The data support the development of Neurona Therapeutics’ regenerative cell therapy candidate, NRTX-1001, which is being evaluated in an ongoing Phase I/II clinical trial of a one-time dose in subjects with drug-resistant MTLE (NCT05135091). The preclinical data were published today in Cell Stem Cell as a Clinical and Translational Report titled “Human pallial MGE-type GABAergic interneuron cell the.

这些数据支持Neurona Therapeutics的再生细胞治疗候选药物NRTX-1001的开发，该药物正在进行中的I/II期临床试验中对具有耐药性MTLE（NCT05135091）的受试者进行一次性剂量的评估。临床前数据今天作为临床和转化报告发表在《细胞干细胞》上，标题为“人苍白MGE型GABA能中间神经元细胞”。